KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants with Non-Small Cell Lung Cancer (NSCLC) with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Trial Identifier: 3475-01J
Sponsor: MSD
Start Date: December 2025
Primary Completion Date: January 2033
Study Completion Date: January 2033
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary

Trial Locations

Country Location
Korea, Republic of, Seoul Seoul, Korea, Republic of, 03722
Ukraine, Cherkaska oblast Cherkasy, Cherkaska oblast, Ukraine, 18009
Ukraine, Dnipropetrovska oblast Kryvyi Rih, Dnipropetrovska oblast, Ukraine, 50000
Ukraine, Ivano-Frankivska oblast Ivano-Frankivsk, Ivano-Frankivska oblast, Ukraine, 76018
Ukraine, Kyiv Kyiv, Ukraine, 03022
Ukraine, Kyiv Kyiv, Ukraine, 03151
Ukraine, Vinnytska oblast Vinnitsya, Vinnytska oblast, Ukraine, 21029
United States, FL Clermont, FL, United States, 34711